作者: W John Edmunds , Marc Brisson , Alessia Melegaro , Nigel J Gay , None
DOI: 10.1016/S0264-410X(01)00473-X
关键词: Vaccination 、 Cost effectiveness 、 Pediatrics 、 Mortality rate 、 Economic evaluation 、 Booster (rocketry) 、 Epidemiology 、 Whooping cough 、 Acellular pertussis 、 Medicine
摘要: A cost-effectiveness analysis of the introduction acellular pertussis booster doses at either 4 or 15 years age was performed. transmission dynamic model used to predict level indirect protection in those too young be vaccinated. Multivariate sensitivity analyses were In England and Wales there are an estimated 35,000 general practitioner (GP) consultations, 5500 inpatient days, nine deaths annually attributable pertussis, despite high levels coverage for primary course (approximately 95%). Around 80% bed-days 90% occur immunised (< 3 months age). The is expected reduce morbidity mortality younger groups by 40-100%, 0-100%. From perspective health care provider, roughly 50% simulations result a cost per life-year gained less than 10,000 pounds vaccination years, corresponding proportion being only 35%. Apart from degree most sensitive discount rate, price vaccine, rate. Significant uncertainty remains regarding epidemiology impact doses. Nevertheless, boosters, particularly has potential cost-effective UK.